Novo Nordisk

News

Novo Nordisk CEO agrees to testify on semaglutide pricing

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabete

News

Scotland first UK nation to clear Mounjaro use for obesity

Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.

News

Second fire at Novo Nordisk in a week now under control

Firefighters have been able to extinguish a fire that raged through an office building at the site of Novo Nordisk’s headquarters in Denmark, although it will not survive

News

Obesity drugs could bankrupt US healthcare, says Sanders

A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s

News

Semaglutide heart benefits may go beyond weight loss

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

Novo Nordisk CEO agrees to testify on semaglutide pricing

Scotland first UK nation to clear Mounjaro use for obesity

Second fire at Novo Nordisk in a week now under control

Obesity drugs could bankrupt US healthcare, says Sanders

Semaglutide heart benefits may go beyond weight loss

Wegovy sales double, as starting restrictions start to lift

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks